<SEC-DOCUMENT>0001104659-25-035581.txt : 20250416
<SEC-HEADER>0001104659-25-035581.hdr.sgml : 20250416
<ACCEPTANCE-DATETIME>20250416173754
ACCESSION NUMBER:		0001104659-25-035581
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250416
DATE AS OF CHANGE:		20250416

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88402
		FILM NUMBER:		25843718

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SATTERFIELD THOMAS A JR
		CENTRAL INDEX KEY:			0001132317
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	MAIL ADDRESS:	
		STREET 1:		2609 CALDWELL MILL LN
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35243
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SATTERFIELD THOMAS A JR -->
          <cik>0001132317</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>04/14/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001512762</issuerCik>
        <issuerName>Coherus BioSciences, Inc.</issuerName>
        <issuerCusip>19249H103</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>333 Twin Dolphin Drive, Suite 600</com:street1>
          <com:city>Redwood City</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94065</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>585000.00</soleVotingPower>
        <sharedVotingPower>5424514.00</sharedVotingPower>
        <soleDispositivePower>585000.00</soleDispositivePower>
        <sharedDispositivePower>5424514.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6009514.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.2</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>* Based on 115,896,849 shares of common stock of the issuer outstanding as of February 28, 2025, as reported by the issuer on its Annual Report on Form 10-K for the year ended December 31, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Coherus BioSciences, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Thomas A. Satterfield, Jr.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>15 Colley Cove Drive
Gulf Breeze, FL 32561</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Incorporated by reference from Item 4 of the Cover Page.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Incorporated by reference from Item 9 of the Cover Page.</amountBeneficiallyOwned>
        <classPercent>Incorporated by reference from Item 11 of the Cover Page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Incorporated by reference from Item 5 of the Cover Page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Incorporated by reference from Item 6 of the Cover Page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Incorporated by reference from Item 7 of the Cover Page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Incorporated by reference from Item 8 of the Cover Page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 100,000 shares are held jointly with Rebecca S. Satterfield, Mr. Satterfield's spouse; 750,000 shares are held by Tomsat Investment &amp; Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 2,200,000 shares are held by Caldwell Mill Opportunity Fund, which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 1,612,514 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.

Additionally, Mr. Satterfield has limited powers of attorney for voting and disposition purposes with respect to the following shares: Thomas A. Satterfield, Sr. (200,000 shares); Rebecca S. Satterfield (65,000); Parker Satterfield (32,000 shares); Jeanette Satterfield Kaiser (155,000 shares); Richard W. Kaiser (65,000 shares); Rita Phifer (70,000 shares); Parker Little Trust (10,000 shares); Lola Little Trust (10,000 shares); Henry Beck (30,000 shares); John and Angela Picton (50,000); Christy Beard (7,000); Paula and Gene Colley (25,000); Glenna and Jesse Colley (35,000); Alex Flannery (4,000); and Camile Richards (4,000). These individuals and entities have the right to receive or the power to direct the receipt of the proceeds from the sale of their respective shares.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas A. Satterfield, Jr.</signature>
        <title>Thomas A. Satterfield, Jr.</title>
        <date>04/16/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
